Source: Annual Congress 2007 - Pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Rioseco, M. Rubilar, F. Verbal, C. Pedreros, R. Lopez (Talcahuano, Chile). Pulmonary arterial hypertension (PAH) among end state renal disease (ESRD) patients under chronic hemodyalisis (HD). Eur Respir J 2007; 30: Suppl. 51, 2089

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary hypertension (PH) in end-stage renal (ESRD) patients receiving dialysis: prevalence and clinical significance Source: Eur Respir J 2007; 30: Suppl. 51, 345s Year: 2007 Pulmonary hypertension (PH) in chronic hemodialysis (CHD) patients is associated with inflammatory markers and volume overload Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Increased prevalence of obstructive airways disease (OAD) in patients with ischemic heart disease (IHD) and hypertension (HT) Source: Eur Respir J 2007; 30: Suppl. 51, 122s Year: 2007 Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Impact of borderline (BL) pulmonary hypertension (PH) in chronic lung diseases (CLD). Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Frequency and features of formation of chronic kidney disease (CKD) in patients with chronic obstructive pulmonary disease. Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases Year: 2019 Effects of amlodipine on pulmonary haemodynamics in pulmonary hypertension (PH) secondary to chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 27s Year: 2002 Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases Year: 2016 Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD) Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD Year: 2011 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019 Comparison of pulmonary hypertension (PH) associated to chronic lung disease to other PH groups Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Influence of bronchodilators on pulmonary hypertension (PH) in patients with moderate and severe chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 310s Year: 2005 HRQoL in adult patients with Eisenmenger syndrome (ES) compared to patients with primary pulmonary hypertension (PPH) or post-embolic pulmonary hypertension (PEPH) Source: Eur Respir J 2002; 20: Suppl. 38, 455s Year: 2002 Increased arterial stiffness in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 65s Year: 2006 Inflammatory biomarkers in patients with COPD and pulmonary hypertension (PH). Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Evidence of renal and pulmonary endothelial dysfunction in chronic obstructive pulmonary disease (COPD) Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 The state of patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2007; 30: Suppl. 51, 547s Year: 2007